IP Library Granted Patent US 8,987,377
Granted Patent B2
US 8,987,377 · App. 13/885,737 · Granted Mar 24, 2015

Poly(amide) polymers for the delivery of oligonucleotides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,987,377
App. No.
13/885,737
Granted
Mar 24, 2015
Kind
B2
Abstract

The present invention provides poly(amide) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.

Claims (47)

1. A polymer comprising Formula Z:

wherein:

x is 2 to 1000;

y is 2 to 1000;

R 1 is a cationic component;

R 2 is an aliphatic component selected from the group consisting of ethyl, propyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, cholesterol, lipid chains, benzyl, benzyl propanoate, benzyl acetate, isopropyl, 2-methylpropane, 2-methylbutane, isobutyl, 2-n-butyl, benzyl, 4-methyl phenol, ethylbenzene, 1-fluoro-4-methylbenzene, 4-methylbiphenyl, 2-methylnaphthalene, 1-methylnaphthalene, 5-ethyl-1-H-imidazole, 4-methyl imidazole, and 2-methyl indole;

R a is independently selected from R 1 and R 2 ;

R b is independently selected from R 1 and R 2 ;

R c is independently selected from R 1 and R 2 ; and

R d is independently selected from R 1 and R 2 ;

or stereoisomer thereof.

2. A polymer according to claim 1 comprising Formula Z′:

wherein:

x is 2 to 1000;

y is 2 to 1000;

R is an initiator;

R′ is an end group;

R 1 is a cationic component;

R 2 is an aliphatic component selected from the group consisting of ethyl, propyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, cholesterol, lipid chains, benzyl, benzyl propanoate, benzyl acetate, isopropyl, 2-methylpropane, 2-methylbutane, isobutyl, 2-n-butyl, benzyl, 4-methyl phenol, ethylbenzene, 1-fluoro-4-methylbenzene, 4-methylbiphenyl, 2-methylnaphthalene, 1-methylnaphthalene, 5-ethyl-1-H-imidazole, 4-methyl imidazole, and 2-methyl indole;

R a is independently selected from R 1 and R 2 ;

R b is independently selected from R 1 and R 2 ;

R c is independently selected from R 1 and R 2 ; and

R d is independently selected from R 1 and R 2 ;

or stereoisomer thereof.

3. A polymer according to claim 2 comprising Formula Z″:

wherein:

x is 2 to 250;

y is 2 to 250;

R is an initiator;

R′ is an end group; and

R 2 is an aliphatic component selected from the group consisting of ethyl, propyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, cholesterol, lipid chains, benzyl, benzyl propanoate, benzyl acetate, isopropyl, 2-methylpropane, 2-methylbutane, isobutyl, 2-n-butyl, benzyl, 4-methyl phenol, ethylbenzene, 1-fluoro-4-methylbenzene, 4-methylbiphenyl, 2-methylnaphthalene, 1-methylnaphthalene, 5-ethyl-1-H-imidazole, 4-methyl imidazole, and 2-methyl indole;

or stereoisomer thereof.

4. A polymer conjugate composition comprising the polymer of Formula Z of claim 1 , a linker and an oligonucleotide.

5. The polymer conjugate composition of claim 4 further comprising a masking agent.

6. The polymer conjugate composion of claim 4 further comprising a targeting ligand.

7. A polymer conjugate composition of claim 4 further comprising a masking agent and a targeting ligand.

8. A polymer conjugate composition made by the 1) synthesis of an activated polymer comprising Formula Z of claim 1 ; 2 ) synthesis of an activated oligonucleotide; and 3) conjugation of the activated polymer with the activated oligonucleotide; optionally including the addition of a masking agent and/or a targeting ligand.

9. A polymer according to claim 1 , wherein R 1 is independently an amine or a nitrogen heterocycle.

10. A polymer according to claim 1 , wherein R 1 is selected from the group consisting of methyl amine, ethyl amine, propyl amine, butylamine, pentyl amine, hexyl amine, heptyl amine, octyl amine, nonyl amine, decyl amine, undecyl amine, dodecyl amine, tridecyl amine, tetradecyl amine, pentadecyl amine, hexadecyl amine, heptadecyl amine, octadecyl amine, 2-(2-aminoethoxy)ethyl, 2-(1H-imidazol-4-yl)ethyl, 2-[2-(2-aminoethoxy) ethoxy]ethyl, 3-amino-2-hydroxypropyl, 2-aminoethyl, 4-aminobutyl, 6-aminohexyl, 8-aminooctyl, 10-aminodecyl, and 1-methyl-2-imidazole modified ornithine.

11. A polymer according to claim 1 , wherein R 2 is selected from the group consisting of isopropyl, benzyl, 4-methyl phenol, 4-methyl imidazole, and 2-methyl indole.

12. A polymer according to claim 2 , wherein R 1 is an amine or a nitrogen heterocycle.

13. A polymer according to claim 2 , wherein R 1 is selected from the group consisting of methyl amine, ethyl amine, propyl amine, butylamine, pentyl amine, hexyl amine, heptyl amine, octyl amine, nonyl amine, decyl amine, undecyl amine, dodecyl amine, tridecyl amine, tetradecyl amine, pentadecyl amine, hexadecyl amine, heptadecyl amine, octadecyl amine, 2-(2-aminoethoxy)ethyl, 2-(1H-imidazol-4-yl)ethyl, 2-[2-(2-aminoethoxy)ethoxy]ethyl, 3-amino-2-hydroxypropyl, 2-aminoethyl, 4-aminobutyl, 6-aminohexyl, 8-aminooctyl, 10-aminodecyl, and 1-methyl-2-imidazole modified ornithine.

14. A polymer according to claim 2 , wherein R 2 is selected from the group consisting of isopropyl, benzyl, 4-methyl phenol, 4-methyl imidazole, and 2-methyl indole.

15. A polymer according to claim 2 , wherein R is an amine, alcohol, water, alkali halide, alkoxide, hydroxide, or a transition metal initiator.

16. A polymer according to claim 2 , wherein R′ is hydrogen or carboxylate.

17. A polymer according to claim 3 , wherein R is n-butylamine or mPEG-amine.

18. A polymer according to claim 3 , wherein R 2 is selected from the group consisting of:

Assignments (3)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2014
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 032584/0215 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2013
From: BARRETT, STEPHANIE E.; BUSUEK, MARINA; COLLETTI, STEVEN L.; GARBACCIO, ROBERT M.; GUIDRY, ERIN N.; KOWTONIUK, ROBERT A.; LIAO, JING; PARISH, CRAIG A.; PARMAR, RUBINA G.; PEI, TAO; SCHLOSSER, KEVIN M.; TELLERS, DAVID M.; TOBIAS, SANDRA C.; TRUONG, QUANG T.; WALDMAN, JACOB H.; WANG, WEIMIN; WILLIAMS, J. MICHAEL
To: MERCK SHARP & DOHME CORP.
Reel/Frame 030587/0647 →